Size | Price | Stock | Qty |
---|---|---|---|
2g |
|
||
5g |
|
||
50g |
|
||
100g |
|
||
200g |
|
||
Other Sizes |
|
Purity: ≥98%
Adenine (formerly NSC 14666; NSC-14666; NSC14666; 6-Aminopurine; Vitamin B4), one of the four chemical/nucleobases in DNA, is a purine derivative and a nucleobase with a variety of functions in biochemistry. In order to determine whether boron stimulates yeast growth, adenine is used as an active ingredient in boron-deficient media to grow yeast. As vitamin B4 and a local antiseptic, it works well. It also plays a role in the microbial assessment of niacin. In order to study the effects of dietary adenine overload, adult rats are also given it as a food supplement.
Targets |
Human Endogenous Metabolite; Microbial Metabolite
|
---|---|
ln Vivo |
Animal models with elevated uric acid can be created by using adenine.
|
References |
[1]. ORO J, et al. Synthesis of purines under possible primitive earth conditions. I. Adenine from hydrogen cyanide. Arch Biochem Biophys. 1961 Aug;94:217-27.
[2]. Griffiths AJF, et al. An Introduction to Genetic Analysis. 7th edition. New York: W. H. Freeman; 2000. Structure of DNA. [3]. Reader V. The assay of vitamin B(4). Biochem J. 1930;24(6):1827-31. |
Molecular Formula |
C5H5N5
|
|
---|---|---|
Molecular Weight |
135.13
|
|
Exact Mass |
135.05
|
|
Elemental Analysis |
C, 44.44; H, 3.73; N, 51.83
|
|
CAS # |
73-24-5
|
|
Related CAS # |
2922-28-3;321-30-2
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=NC2=NC=NC(=C2N1)N
|
|
InChi Key |
GFFGJBXGBJISGV-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
|
|
Chemical Name |
7H-purin-6-amine;sulfuric acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (7.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 7.4003 mL | 37.0014 mL | 74.0028 mL | |
5 mM | 1.4801 mL | 7.4003 mL | 14.8006 mL | |
10 mM | 0.7400 mL | 3.7001 mL | 7.4003 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03799705 | Active Recruiting |
N/A | Vacterl Association Congenital Malformation |
Mayo Clinic | December 1, 2019 | N/A |
NCT06005350 | Not yet recruiting | Dietary Supplement: Niagen Other: Placebo |
NAD | Charite University, Berlin, Germany |
September 4, 2023 | Not Applicable |
NCT04691986 | Recruiting | Dietary Supplement: Nicotinamide Riboside Other: Placebo |
Muscle Quality and NAD+ Content Sarcopenia |
VA Office of Research and Development |
September 1, 2023 | Not Applicable |
NCT06065852 | Recruiting | N/A | Cystinosis Cystinuria |
UK Kidney Association | November 6, 2009 | N/A |
NCT02752633 | Completed | Drug: Allopurinol Drug: Febuxostat |
Adenine Phosphoribosyltransferase Deficiency |
Landspitali University Hospital | May 2013 | Phase 4 |